Abatacept Rescue Therapy in Kidney Transplant Recipients: A Case Series of Five Patients.
作者信息
Uro-Coste Charlotte, Atenza Alba, Heng Anne-Elisabeth, Rouzaire Paul-Olivier, Garrouste Cyril
机构信息
Department of Nephrology, Dialysis and Transplantation, Clermont-Ferrand, France.
EA 7453 CHELTER, Clermont-Ferrand, France.
出版信息
Transpl Int. 2022 Aug 12;35:10681. doi: 10.3389/ti.2022.10681. eCollection 2022.
Abstract
摘要
相似文献
1
Abatacept Rescue Therapy in Kidney Transplant Recipients: A Case Series of Five Patients.阿巴西普挽救治疗肾移植受者：5例患者的病例系列
Transpl Int. 2022 Aug 12;35:10681. doi: 10.3389/ti.2022.10681. eCollection 2022.
2
Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.巴利昔单抗治疗肾移植后钙调磷酸酶抑制剂治疗失败后的挽救性免疫抑制。
Am J Transplant. 2019 Aug;19(8):2342-2349. doi: 10.1111/ajt.15319. Epub 2019 Mar 12.
3
Belatacept conversion in adolescent and young adult kidney transplant recipients.青少年及青年肾移植受者转换使用贝拉西普的情况。
Clin Transplant. 2023 Mar;37(3):e14882. doi: 10.1111/ctr.14882. Epub 2022 Dec 28.
4
Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.微血管炎症是钙调磷酸酶抑制剂方案转换为贝利尤单抗方案后非常晚才发生的肾移植受者的一个风险因素。
BMC Nephrol. 2020 Aug 20;21(1):354. doi: 10.1186/s12882-020-01992-6.
5
Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.肾移植受者从他克莫司晚期转换为基于贝拉西普的免疫抑制方案可改善肾功能、酸碱紊乱和矿物质-骨代谢。
J Nephrol. 2017 Aug;30(4):607-615. doi: 10.1007/s40620-017-0411-0. Epub 2017 May 24.
6
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.在肾移植受者中从钙调磷酸酶抑制剂转换至贝利尤单抗后的 3 年安全性和疗效结局：一项 2 期随机试验的结果。
Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23.
7
Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv score >2): a retrospective cohort study.贝那普利塞抢救治疗伴血管病变（Banff cv 评分>2）的肾移植受者：一项回顾性队列研究。
Nephrol Dial Transplant. 2023 Feb 13;38(2):481-490. doi: 10.1093/ndt/gfac178.
8
Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.钙调磷酸酶抑制剂转换为以贝利尤单抗为基础的免疫抑制方案在 HLA 致敏肾移植受者中的疗效。
Transplantation. 2020 Jul;104(7):1500-1507. doi: 10.1097/TP.0000000000002976.
9
Experience with belatacept rescue therapy in kidney transplant recipients.肾移植受者使用贝拉西普挽救治疗的经验。
Transpl Int. 2016 Nov;29(11):1184-1195. doi: 10.1111/tri.12822. Epub 2016 Sep 14.
10
Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France.在法国第一次 COVID-19 居家令期间，将住院静脉注射贝那普利特转换为皮下注射阿巴他赛。
Transpl Int. 2023 Jul 24;36:11328. doi: 10.3389/ti.2023.11328. eCollection 2023.
引用本文的文献
1
Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future.共刺激阻断与实体器官移植：过去、现在与未来
Kidney Int Rep. 2023 Sep 3;8(12):2529-2545. doi: 10.1016/j.ekir.2023.08.037. eCollection 2023 Dec.
2
Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report.托珠单抗在维持性血液透析类风湿关节炎患者中的安全有效应用：一例报告。
Medicina (Kaunas). 2023 Aug 23;59(9):1517. doi: 10.3390/medicina59091517.
3
Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France.在法国第一次 COVID-19 居家令期间，将住院静脉注射贝那普利特转换为皮下注射阿巴他赛。
Transpl Int. 2023 Jul 24;36:11328. doi: 10.3389/ti.2023.11328. eCollection 2023.
4
Back to the Future With Co-Stimulation Blockade.共刺激阻断疗法的未来展望。
Transpl Int. 2023 Jul 24;36:11752. doi: 10.3389/ti.2023.11752. eCollection 2023.
本文引用的文献
1
Transplant Recipient Experience With Belatacept Therapy.移植受者接受贝利尤单抗治疗的体验。
Transplant Proc. 2022 Jul-Aug;54(6):1604-1608. doi: 10.1016/j.transproceed.2021.12.046. Epub 2022 Mar 9.
2
CD86 occupancy in belatacept-treated kidney transplant patients is not associated with clinical and infectious outcomes.在接受贝利尤单抗治疗的肾移植患者中，CD86 占有率与临床和感染结局无关。
Am J Transplant. 2022 Jun;22(6):1691-1698. doi: 10.1111/ajt.17005. Epub 2022 Feb 28.
3
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.钙调磷酸酶抑制剂向贝利尤单抗为基础的维持性免疫抑制方案转换在肾移植受者中的应用：一项随机 3b 期临床试验
J Am Soc Nephrol. 2021 Dec 1;32(12):3252-3264. doi: 10.1681/ASN.2021050628.
4
Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept.在转换为贝利尤单抗后，肾移植受者中 CMV 疾病的发病率和表现形式增加。
Am J Transplant. 2021 Jul;21(7):2448-2458. doi: 10.1111/ajt.16430. Epub 2021 Jan 2.
5
Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.巴利昔单抗治疗肾移植后钙调磷酸酶抑制剂治疗失败后的挽救性免疫抑制。
Am J Transplant. 2019 Aug;19(8):2342-2349. doi: 10.1111/ajt.15319. Epub 2019 Mar 12.
6
Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study.在维持性肾移植患者中转换为贝利尤单抗：一项回顾性多中心欧洲研究。
Transplantation. 2018 Sep;102(9):1545-1552. doi: 10.1097/TP.0000000000002192.
7
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.体重指数与静脉或皮下注射阿巴西普治疗类风湿关节炎患者的临床应答。
Clin Rheumatol. 2017 Dec;36(12):2655-2665. doi: 10.1007/s10067-017-3788-1. Epub 2017 Aug 18.
8
Abatacept: A Review in Rheumatoid Arthritis.阿巴西普：类风湿关节炎的治疗药物。
Drugs. 2017 Jul;77(11):1221-1233. doi: 10.1007/s40265-017-0775-4.
9
Belatacept and Long-Term Outcomes in Kidney Transplantation.贝利尤单抗与肾移植的长期结局。
N Engl J Med. 2016 Jan 28;374(4):333-43. doi: 10.1056/NEJMoa1506027.
10
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.在肾移植受者中从钙调磷酸酶抑制剂为基础的方案转换为贝利尤单抗为基础的方案：一项随机 II 期研究。
Clin J Am Soc Nephrol. 2011 Feb;6(2):430-9. doi: 10.2215/CJN.05840710. Epub 2010 Nov 4.
Zotero 插件